Follow the Akili, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 8 July 2024 (U). Among the most active insiders: Studer Jacqueline. Every trade is openly available.
41
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€5,900
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Akili, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
42Σ signal
Buys n/a€5,900 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,010 of 28,932 companies
31.0
score / 100
Value
23
Quality
39
FCF yld-4.0%
Earn yld-5.1%
EV/EBITDA·
ROE-40%
Gross mgn51%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
5,395 shares@ US$1.0943.1% of flowCommon StockSEC:0000899243-23-012259:0
25 of 41 declarations
About Akili, Inc.
Akili, Inc. is a health technology company that develops therapeutic video games to treat cognitive disorders. It is listed on the NASDAQ under the ticker symbol AKLI.